ODS Medical Inc. announces Sentry™ System prototype for real-time Raman spectroscopy receives Health Canada testing authorization
MONTREAL, Aug. 1, 2019 /CNW Telbec/ – ODS Medical Inc. is pleased to announce that the company has received Investigational Testing Authorization from Health Canada for its SentryTM System Prototype. With this authorization, ODS Medical will be able to launch a new clinical study in brain cancer surgeries at The Neuro (Montreal Neurological Institute and Hospital). The study is scheduled to start later this month. Dr. Kevin Petrecca, Chief of Neurosurgery at the McGill University Health Centre, and ODS Medical Inc. co-founder, is the study’s principal investigator…
http://www.newswire.ca/en/releases/archive/August2019/01/c6601.html
In The Press
February 04, 2022
AI ‘Fingerprinting’ Fights Back Against Hard-to-Detect Cancers
Read More
November 25, 2021
Detecting the previously undetectable
Read More
November 19, 2021
Made in Quebec: Illuminating hidden brain cancer cells
Read More
November 09, 2021
ODS Medical Inc has rebranded as Reveal Surgical
Read More
September 01, 2020
ODS Medical, Inc. closes a new financing round to further support product development diversification of applications
Read More
May 27, 2019
Innovation, Science and Economic Development Canada announces $49 Million investment in DHDP
Read More
October 25, 2018
ODS Medical joins forces with two American Giants
Read More
July 01, 2018
ODS Medical is a 2018 Medtech Innovator Showcase Company
Read More
January 12, 2018
Frédéric Leblond in the running for discovery of the year
Read More
June 29, 2017
Montreal-developed probe could be breakthrough in finding cancer (Montreal CTV News)
Read More